TIL

by ASTCT Talks

In this episode of ASTCT Talks, host Daniel Olson, MD, of the University of Chicago, is joined by Stephanie Goff, MD, of the National Cancer Institute (NCI), and Allison Betof, MD, PhD, of...

TIL

Potent Cytotoxic Tumor-Infiltrating Lymphocytes Can Be Generated From Immune-Excluded Chondrosarcomas Using Regulatable Membrane-Bound IL15

by Alex Kadhim

Reporting in Cancer Immunology Research, researchers have demonstrated that potent cytotoxic tumor-infiltrating lymphocytes (TILs) can be generated from immune-excluded chondrosarcomas using...

TIL

TIL Cell Therapy in HIV Positive Patient With Metastatic Melanoma: Case Report

by Alex Kadhim

Researchers at Northwestern University, with collaborators from the University of Chicago and McGaw Medical Center, have reported the first known case of tumor-infiltrating lymphocyte (TIL)...

TIL

Real-World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (TIL) Therapy Program Using Commercial Lifileucel

by Alex Kadhim

This real-world study demonstrates that lifileucel TIL therapy can deliver strong responses in advanced melanoma, with high response rates and encouraging survival among treated patients. However,...

TIL

Proteostasis Sustains T Cell Differentiation Potential and Tumor-Infiltrating Lymphocyte Function

by Alex Kadhim

New findings highlight proteostasis as a key driver of T cell differentiation and antitumor function, identifying protein-quality control as a critical factor in preventing T cell exhaustion. By...

TIL

Adoptive Cell Therapies Offer ‘New Hope’ for Patients With Limited Treatment Options

by C. Brooke Adams, PharmD, BCOP

The cellular therapy landscape continues to evolve beyond hematologic malignancies, now making significant progress in solid tumor treatment. Certain characteristics seen in solid tumors...

TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

Topics to Explore

TIL